Campbell W N, Hendrix E, Cryz S, Cross A S
Department of Medicine, University of Maryland School of Medicine, Baltimore, USA.
Clin Infect Dis. 1996 Jul;23(1):179-81. doi: 10.1093/clinids/23.1.179.
We measured the antibody response in 10 victims of acute blunt trauma and penetrating trauma who were immunized against Klebsiella pneumoniae and Pseudomonas species within 72 hours of injury. The two vaccines, which were previously shown to be safe and immunogenic in uninjured humans, were a 24-valent K. pneumoniae capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide-toxin A conjugate vaccine. The patients were between 18 and 44 years of age, had Injury Severity Scores that ranged between 9 and 34, and did not have chronic infections or malignancies. On days 14 and 28 after immunization, all patients had a response of greater than fourfold to at least six of the nine Pseudomonas vaccine antigens. Half of the patients responded to eight of the nine antigens. Nine patients responded to at least 18 of 24 Klebsiella antigens, and seven patients responded to 22 of the 24 antigens. No important side effects were attributed to the vaccines. The results of this preliminary study indicate that active immunization against potential pathogens is possible in victims of acute trauma.
我们对10名急性钝性创伤和穿透性创伤患者的抗体反应进行了测量，这些患者在受伤后72小时内接种了针对肺炎克雷伯菌和假单胞菌属的疫苗。这两种疫苗，先前已证明在未受伤的人类中是安全且具有免疫原性的，一种是24价肺炎克雷伯菌荚膜多糖疫苗，另一种是8价假单胞菌O-多糖-毒素A结合疫苗。患者年龄在18至44岁之间，损伤严重程度评分在9至34之间，且没有慢性感染或恶性肿瘤。在免疫接种后的第14天和第28天，所有患者对9种假单胞菌疫苗抗原中的至少6种产生了四倍以上的反应。一半的患者对9种抗原中的8种有反应。9名患者对24种肺炎克雷伯菌抗原中的至少18种有反应，7名患者对24种抗原中的22种有反应。没有发现疫苗引起的重要副作用。这项初步研究的结果表明，急性创伤患者对潜在病原体进行主动免疫是可行的。
